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Many African countries, through their development plans, have prioritised access to affordable 
healthcare services. However, the 
realisation of these aspirations has 
been constrained due to the high costs 
of imported medicines, which not only 
increase the health burden but also have 
negative implications on access and 
affordability of medicines. Affordability 
is important since up to 90% of the 
population buys medicines through out-
of-pocket payments. 
As a result, many African countries 
have started initiatives to promote 
local pharmaceutical manufacturing, 
to address the issue of high costs 
of imported medicines and to tap 
into additional benefits that local 
pharmaceutical industries can bring, 
such as creation of employment 
opportunities, technology and skills 
transfer and enhancing intra-Africa trade. 
This has led to the establishment of 
about 172 local pharmaceutical firms 
in the ECOWAS region. Nigeria is leading 
with 120 firms, followed by Ghana with 37 
firms, while Senegal and Côte d’Ivoire have 
five firms each. Benin, Burkina Faso, Cape 
Verde and Guinea Conakry have one firm 
each. 
Despite the above high number of local 
firms, currently local production covers 
less than 30% of the demand for medicine 
in the region. Ironically, most of these 
firms operate at less than 40% capacity. 
This is a paradox, illustrating a challenge 
that whereas there is at least 70% unmet 
local market for medicines in the region, 
the existing local firms cannot access it. 
To get answers for this contradiction 
and other related issues, a study was 
commissioned to review the sector 
and propose interventions. The study 
focused on issues of affordability; human 
resources; research and development; 
intellectual property; and technology 
transfer, and covered nine ECOWAS 
countries - Ghana, Nigeria, Senegal, 
Côte d’Ivoire, Togo, Benin, Mali, Guinea 
This policy brief arises from a study 
commissioned by the Scinnovent 
Centre and undertaken by ACTS under 
the auspices of the Science Granting 
Councils Initiative (SGCI).
The study focused on building 
competitive and socially inclusive 
local pharmaceutical industries 
in West Africa and addressed 
five issues: affordability, human 
resources, research and development, 
intellectual property and technology 
transfer.
This policy brief presents findings 
on the human resource situation for 
the pharmaceutical sector in West 
Africa. The policy brief explains the 
current situation and what can be 
done in terms of training, linking 
with diaspora, collaboration and 
partnership with Asian countries 
and building synergy within ECOWAS 
to address the human resource 
requirements for the sector in West 
Africa.
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Conakry and Cape Verde. These 
countries were selected based on 
the existence of at least one local 
pharmaceutical manufacturing 
firm. The study explored the use 
of public health procurement as a 
tool for promoting the growth and 
performance of local pharmaceutical 
production. It was premised on the 
fact that a procurement policy that 
provides preferential treatment 
to local pharmaceutical industries 
would spur more local production of 
essential medicines, reduce the cost 
of medicine and therefore enhance 
access, affordability and social 
inclusion. 
The study achieved the following: 
• Documented the existence of 
procurement policy incentives 
that promote local pharmaceutical 
industries. 
• Looked at the impact on 
production and consumption 
patterns; growth and capabilities 
of the local pharmaceutical 
manufacturing; and ability of the 
local manufacturing to serve the 
poor. 
• Documented experiences, best 
practices and success stories 
from those countries that have 
implemented such policies. 





The required information was 
obtained through desk study, 
interviews, and stakeholders’ 
consultations, in five ECOWAS 
countries (Nigeria, Ghana, Cote 
d’Ivoire, Senegal, and Togo) by 
national consultants. In addition, a 
scoping desk study was undertaken 
in Mali, Guinea Conakry, Cape Verde 
and Benin. In addition to national/in-
country studies, comparative country 
studies were also used to document 
the differences and similarities in 
approaches between Anglophone and 
Francophone countries.
Benchmarking studies were also 
undertaken targeting India, China, 
Brazil, Morocco and Ethiopia, to 
identify some best practices. The 
national consultants prepared national 
reports that were moderated during a 
three-day experience sharing amongst 
the five consultants in Abidjan, Côte 
d’Ivoire. The main findings of this 
study are:
1. Procurement policy incentives 
are in place
The study established that, most 
West African countries have in 
place procurement policy incentives 
to support local pharmaceutical 
industries. These are: preferential 
treatment of local companies; ring-
fencing certain products for local 
manufacturing companies; and 
prohibiting importation of medicines 
that are being produced locally.
• Preferential treatment: All the 
countries studied have policy 
incentives that provide between 
5-15% preferential treatments 
of local industries for public 
procurement of medicines. 
In Ghana, for example, the Public 
Procurement Act (Act 914)8 (as 
Amended in 2016) provides a 
margin of preference of 15% to 
locally produced medicines under 
the National and International 
Competitive Tendering processes. 
In Nigeria, the Public Procurement 
Act (2007) has a provision for 
a domestic preference policy 
that gives an extra margin of 
7.5% for goods and 15% for 
services on prices for domestic 
suppliers when bidding with their 
foreign counterparts under an 
international competitive bid, and 
has been used to support local 
pharmaceutical industries. 
In Senegal, there is the National 
Preference Programme, under 
which, local industries are 
allowed a margin of 5-15% during 
international tenders. From the 
first review of the trade policies 




and practices of WAEMU held 
in October 2017, it is reported 
that national preference policy 
is applicable to all members of 
the West African Economic and 
Monetary Union, WAEMU (Benin, 
Burkina Faso, Côte d’Ivoire, 
Guinea-Bissau, Mali, Niger, 
Senegal, and Togo). 
• Ring-fencing of certain products: 
All the countries have recently 
applied the policy of ring-
fencing certain products for local 
companies. 
For example, Ghana, in August 
2017, through a Gazette Notice 
No 74 (LI 2255)9, ring-fenced 49 
products to restrict them to only 
local manufacturing with the hope 
that this policy intervention will 
bring down the prices of those 
products.
Similarly, Senegal, in collaboration 
with the industries developed 
in 2017 a national tender 
programme, in which, a list of 60 
products have been ring-fenced 
for the local industries. Again, this 
policy is applicable to all WAEMU 
countries. 
• Prohibiting importation of certain 
products: Finally, West African 
Economic and Monetary Union 
(WAEMU) countries, are using 
national preference agreements, 
which prohibit importation of 
medicines with the same active 
ingredient, pharmaceutical 
formula and dosage as those 
manufactured locally, to support 
the local pharmaceutical 
industries. It is said that this policy 
is also applicable to other WAEMU 
countries. 
This is with reference to the 
trade policy review of October 
2017. It is further noted that 
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WAEMU trade in local products 
is, in principle, free of duty and 
import taxes. Tariff preferences 
for processed products require 
two prior approvals (of the 
product and the manufacturer) in 
addition to the certificate of origin 
to guarantee the origin of the 
product and the nationality of the 
manufacturer.
• Apart from the above incentives, 
all the countries have put in 
place national health insurance 
schemes, which can be an 
important tool for enhancing 
access and affordability. 
For example, the Ghana National 
Health Insurance Schemes, 
NHIS10 is a major player in the 
Pharmaceutical sector and a 
determinant on the promotion 
of LPP since more than 50% of 
pharmaceuticals to consumers are 
financed by it.
As a result, following the 
introduction of a policy that 
exempts VAT payments on some 
selected finished pharmaceutical 
products (FPP) for manufacturers, 
NHIS is in discussion with the 
stakeholders to reduce their 
published prices by 30%.
From the Francophone side, the 
Government of Senegal has set 
up the Universal Health Coverage 
(CMU) programme to enable 
medical coverage of populations, 
in particular, the rural population 
and the informal sector through 
community health. (Source: 
Ministerial circular MSAS Sept 
2019).
2. The impact of the preferential 
procurement policies on local 
pharmaceutical industries is 
minimal 
This is attributed to low level of 
competitiveness, low production 
capacities, and taxes on finished 
pharmaceutical products. There are 
also country specific factors.
• Low Competitiveness: Local 
manufacturers in the nine 
countries are not able to take 
advantage of the procurement 
preferential policies due to lack 
of competitiveness of the locally 
produced products compared to 
imported drugs. 
This is attributed to three reasons: 
First: the cost of energy and water 
is significantly higher in ECOWAS 
than in India and China, the main 
sources of imported medicines.
Second: all pharmaceutical 
industries in the region import 
over 80% of their inputs, mainly 
from the two competitor 
countries (India and China). 
Almost all machinery and 
equipment, laboratory equipment 
and reagents, and raw production 
materials, including active 
pharmaceutical ingredients 
(APIs), aluminum foil for blister 
packaging, other labelling 
materials, and excipients are 
imported.
Third: due to the long duration 
of imports of inputs, local 
industries are forced to hold large 
inventories to ensure steady 
production. This has a significant 
consequence on working capital 
given the high cost of finance in 
African countries. 
• Production Capacity: Local 
industries have not adequately 
benefitted from the national 
tender programme of ring-
fencing products, since they do 
not have in their portfolio all the 
60 requested products which 
is a generalised principle in the 
region. 
• VAT on finished products: Since 
1969, World Health Assembly VAT 
has been charged on the finished 
pharmaceutical products, which 
increased the prices of the drugs 
produced locally. However, this 
has since been reviewed in the 
ECOWAS countries. For example, 
in 2018, the Government of 
11   http://www.moh.gov.gh/moh-launches-revised-
national-medicines-policy/
Ghana launched the third edition 
of the National Medicines Policy 
(NMP)11, which recommended, 
amongst others, VAT exemptions 
on finished pharmaceutical 
products (FPP) and active 
pharmaceutical ingredients (APIs). 
Similarly, WAEMU countries 
have also zero-rated imported 
medicines, granting them 
exemption from customs duties 
and VAT on imports.
• Country specific policies:  In 
Ghana, the margin of preference 
of 15% is limited only to national 
level and excludes regional and 
facility levels which constitute 
almost 50% of the total public 
medicine procurement. Therefore, 
local manufacturers lose out 
at the regional and facility 
procurement levels where the 
margin of preference is not 
considered since they are often 
not very competitive where 
the margin of preference is not 
applied. This means that outside 
the preferential cluster they will 
be locked out and they can only 
access these benefits if a region 
specific policy is established.
3. Building local pharmaceutical 
industry requires better incentives 
and strong protectionist policies
For example, India, China and Brazil 
demonstrate this:
• High customs duties on imported 
products: For example, India 
applies customs duties on 
formulas or rules or statements 
up to 56% on import tariffs. 
Brazil applies 15% on formulas, 
and China has recently imposed 
import tariffs of up to 37% on 
products imported from India.
• Purchasing preferences: Brazil 
manufacturers enjoys preferential 
prices of 25%, whereas Russia 
has introduced measures to 
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ensure that 70% of the products 
purchased by the state are 
manufactured locally and this has 
led many Indian companies to 
consider building manufacturing 
plants in Russia. 
• Prohibition of importation of 
certain medicines: Moroccan 
production currently covers 
nearly 60% of the country’s 
needs. This has been achieved 
mainly through a policy of 
prohibition of importation 
of medicines that could be 
manufactured in Morocco. This 
made multinationals that were 
established in Morocco move to 
the production stage.12
• Export support: In India, 
producers of drug formulations 
receive substantial government 
support to promote exports. 
These include low utility rates and 
working capital loans.
• Mobilisation finances: In Ethiopia, 
if a local pharmaceutical industry 
wins a tender, the government 
provides 30% for mobilisation and 
a letter that can be used to get 
credit facility.
4. Donor subsidies have negative 
impacts on local industries
First, to participate in donor funded 
procurement requires that the 
product must be WHO prequalified. 
Out of more than 172 manufacturing 
companies, only six have products 
that are prequalified. This means that 
the rest cannot access this market. 
Second, where the donor subsidies 
supply a product that is manufactured 
locally, this distorts the market. 
For example, in 2010, the Government 
of Ghana implemented the Affordable 
Medicine Facility-malaria13 policy to 
improve the access of anti-malarials 
at affordable prices. This was an 
innovative global financing mechanism 
for the provision of quality assured 
Artemisinin-based combination 
therapy (ACTs) in eight countries in 
sub-Saharan Africa. At that time, 
a local pharmaceutical company, 
Amponsah Efah Pharmaceutical 
(AEP) had embarked upon upgrades 
of equipment and machinery 
to transition from chloroquine 
production to ACTs. The policy made 
AEP products uncompetitive and 
created huge cash flow challenges for 
the company. 
5. Local industries are losing out on 
donor funded programmes due to 
lack of World Health Organisation 
Certification 
Out of more than 172 manufacturing 
firms, only six have products that 
are prequalified. To improve on the 
situation, several ECOWAS countries 
have embarked on WHO Certification 
Roadmaps, which are supported 
by WHO and UNIDO. For example, 
Ghana, since 2015, is pursuing the 
Ghana Good Manufacturing Practice 
(GMP) Certification Roadmap 2015-
2020.
Ghana greatly relies on the 
Department of Public Safety, for the 
procurement of medicines for malaria, 
TB, HIV/AIDS, and reproductive health. 
However, local companies have not 
participated in the procurement 
processes for these medicines 
since their products are not WHO 
GMP Prequalified. Thus, the donor 
supported segment of the Ghana 
pharmaceutical market has never 
benefited the local pharmaceutical 
companies. It was expected that if the 
roadmap programme had progressed 
as planned most of the companies 
were expected to be WHO GMP 
compliant within five years by 2020.
However, the companies have 
been slow to follow the WHO GMP 
Roadmap and hence their own 
Corrective and Preventive Actions 
(CAPAs) to bridge the gaps identified. 
They complain of unavailability 
of a long term or development 
financing needed for the upgrades. 
In addition, there is also the ECOWAS 
Pharmaceutical GMP Roadmap 
Initiative that was launched in 2017 in 
Accra, Ghana.
12The drug in Africa: how to better respond to the 
issues of accessibility and quality? April 3, 2018 French 
Development Agency.
13Insights into the Affordable Medicines Facility-malaria 
in Ghana: the role of caregivers and licensed chemical 
sellers in four regions. Available at https://malariajournal.
biomedcentral.com/articles.
The objective of the initiative is to 
establish a strong pharmaceutical 
manufacturing industry in the 
ECOWAS region by bringing 
pharmaceutical manufacturers up to 
WHO GMP and other international 
standards in a step-by-step 
individualised improvement program 
to meet the goals of access to quality, 
safe and affordable medicines. 
CONCLUSIONS AND 
RECOMMENDATIONS
The following conclusions and 
recommendations were made from 
the five main findings of the study:
1. All the nine countries reviewed 
have in place procurement 
policy incentives to support 
local pharmaceutical industries 
and enhance access to and 
affordability of medicines through 
lowering of the costs. These are: 
(a) 5-15% preferential 
treatment of local industries for 
procurements of medicines; 
(b) ring-fencing of certain 
products for local industries; and 
(c) prohibiting the importation 
of medicines with the same 
active ingredient, pharmaceutical 
formula and dosage as those 
manufactured locally. 
These interventions by ECOWAS 
countries are laudable and 
demonstrate West African 
governments’ commitment 
towards promoting local 
pharmaceutical industries. 
However, there are still major 
challenges such as inadequate 
funding to upgrade the technical, 
infrastructural and production 
capacities of the local firms; 
lack of effective and efficient 
implementation and enforcement 
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strategies of the available 
polices, regulations. They will 
also need to put in place other 
interventions that enhance the 
competitiveness and inclusion of 
the pharmaceutical firms in the 
region.
2. Despite the above-mentioned 
commendable efforts by ECOWAS 
countries, the desired outcomes 
of these interventions have not 
been realised. This is mainly due 
to weak competitiveness of the 
local products and the limited 
capacity of the local industries. 
To improve on competitiveness 
in ECOWAS countries, there 
is need to intervene at three 
levels. First is to promote local 
production of some of the 
imported inputs. Particular 
attention should be given to the 
active pharmaceutical ingredient, 
which is the most expensive 
component and of which 95% 
is being imported. Promoting 
mutual collaboration between 
the local firms, universities and 
research institutions and foreign 
firms would boost both technical, 
infrastructural and production 
capacities of the local firms.
This can be realised through 
various tax incentives such as, 
duty free import, zero-rated 
VAT, Investment incentives et 
cetera. Second, is to revisit the 
cost of local inputs, particularly 
energy and water; and third is 
to review the VAT policy and 
regulations imposed on finished 
pharmaceutical products both at 
the national and regional level. 
On considering both the 
technical, infrastructural and 
even production capacity of the 
firms it is recommended that 
local pharmaceutical firms should 
consider forming a consortium to 
submit joint bids.
The pharmaceutical manufacturer 
associations should divide the 
products portfolio so that each 
manufacturer has its own list for 
submission. As a consortium, 
they can also consider partnering 
with Indian industries by virtue of 
their local presence and existing 
collaborations to receive bulk 
products and make secondary 
packaging.
3. There are three interesting 
interventions by various ECOWAS 
countries that are worth 
replicating in other African 
countries. 
(a)VAT exemptions on some 
selected FPP introduced by Ghana 
in 2018;
(b)National Health Insurance 
Schemes working together with 
local pharmaceutical industries 
on pricing as well as influencing 
policies (example of Ghana); and
(c)Tax incentives for investment 
in local pharmaceutical industries 
and the application of local 
content policy in Senegal.
4. Three lessons learned from 
elsewhere are worth considering 
by ECOWAS countries and other 
African countries: 
(a) The need for deliberate efforts 
to protect local pharmaceutical 
industries through heavy import 
taxes as done by Brazil, India and 
China;
(b) Using policy on ring-fencing of 
products (purchase preferences) 
to force exporting companies 
to establish local manufacturing 
as was the case in Russia and 
Morocco; and
(c) Provision of mobilisation fund 
and letter of support for accessing 
credit (as is the case in Ethiopia) 
when local companies get 
government contracts.
5. Although donor subsidies 
negatively impact on local 
pharmaceutical industries, donor 
support on provision of medicines 
is a key factor in enhancing access 
to healthcare and affordability and 
can therefore not be wished away. 
However, care should be taken to 
ensure that affected companies 
are supported.
6. WHO Certification is the single 
most critical intervention that can 
unlock huge potential for the local 
pharmaceutical industries. Apart 
from providing access to donor 
funded drug market, it is believed 
that certification will have several 
other benefits. These includes 
providing confidence in potential 
financiers and investors that can 
partner with local industries. 
Therefore, deliberate efforts by 
the governments and industries 
should be invested in the WHO 
certification roadmaps initiated by 
several ECOWAS countries.
SCINNOVENT CENTRE - POLICY BRIEF NO. 3 6
7
SCINNOVENT CENTRE - POLICY BRIEF NO. 3 8
The Scinnovent Centre 
Second Floor, Karen Plains Arcade 
P.O. Box 52486 - 00100, GPO, Nairobi, Kenya
Website: www.scinnovent.org; Tel: +254 020 2173433
	
